BRAIN share successfully starts trading

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Miscellaneous/IPO

2016-02-09 / 14:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

The information contained herein is not for publication, release or
distribution (directly or indirectly) in or into or to persons in the
United States of America, Canada, Japan and Australia or any other
jurisdiction in which publication, release or distribution would be
unlawful.

PRESS RELEASE

BRAIN share successfully starts trading 

Zwingenberg, February 9, 2016: B.R.A.I.N. Biotechnology Research and
Information Network AG ("BRAIN AG"; ISIN DE0005203947 / WKN 520394) had a
successful stock market debut today. The first share price was at 9.15
Euros, and therefore above the issue price of 9 Euro. BRAIN AG is now
listed - as the first German company from the field of bioeconomy - in the
Prime Standard segment of the Frankfurt stock exchange.

A total of 32.5 million Euros (including over-allotments) were placed in
the context of the offering, from which the Company receives gross proceeds
of 31.5 million. BRAIN AG intends to use these proceeds, after deduction of
the IPO expenses, primarily to fund the development of new products and to
enhance the marketing of its own products, such as enzymes, performance
microorganisms and bioactive compounds.

"Many of our initial share subscribers - among them institutional and
private investors from Germany and Europe - have recognized the growth
potential offered by a bio-based economy. We do not want to disappoint the
trust placed in us and will continue our industrialisation strategy at full
throttle. Our pipeline of bio-based solutions, which will make industrial
processes more sustainable, efficient, natural and healthier, is strong
thanks to a current total of 15 programmes. We will consistently continue
to develop them with the proceeds from the IPO," says Dr Jürgen Eck, CEO of
BRAIN AG.

BRAIN AG is one of Europe's leading technology companies in the field of
industrial or "white" biotechnology, the core discipline of the bioeconomy.
A particular growth potential is seen in large parts of the chemical
industry, where experts foresee a rising share of biotechnology products
and procedures. Here, BRAIN AG focuses on the specialty chemicals and the
consumer chemicals divisions, with an emphasis on nutrition, cosmetics and
wound care.

Based on these business activities, BRAIN was classified by Deutsche Börse
as belonging to the Speciality Chemicals sector of the Prime Standard
segment. This sector of the German capital market is characterised by a
remarkable concentration of expertise, something BRAIN may benefit from as
a publicly listed company.

"We are pleased to welcome BRAIN to the Frankfurt Stock Exchange. BRAIN is
the first company form the field of bioeconomy to enrich our stock exchange
list," says Hauke Stars, Member of the Executive Board at Deutsche Boerse
AG.

The BRAIN transaction was the first IPO in Germany this year. The capital
increase of 3.5 million shares was fully placed. Approximately 19 per cent
of the placed shares were allocated to retail investors. The remaining
shares were placed with top-class institutional investors from Germany and
different European countries

"With the floatation of BRAIN we have implemented Germany's first IPO of
the year. Acting as Sole Global Coordinator and Bookrunner, we reached out
to a large circle of European investors even beyond our Franco-German
domestic markets. Thanks to our highly experienced and committed sales
team, we have been able to convey the BRAIN equity story and the bio-based
economy as a whole to the investment community," says René Parmentier, CEO
of ODDO SEYDLER BANK AG, which managed the IPO transaction. "Despite a
highly volatile capital market environment, the final issue price was fixed
within the initial bookbuilding range. We are very happy about this
successful transaction, which may possibly help break the ice for further
IPO transactions," adds Parmentier.

ODDO SEYDLER Bank AG acted as Sole Global Coordinator and Bookrunner in the
BRAIN IPO transaction. Blaettchen Financial Advisory GmbH supported the
Company as IPO consultant, the law firm Hoffmann Liebs Fritsch & Partner
acted as issuer's counsel, and Instinctif Partners supported in the areas
of investor relations & financial communication.

+++ENDS+++

About BRAIN 

BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at
www.brain-biotech.de/en

Contact:

BRAIN Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de

Disclaimer

This document and the information contained herein are for information
purposes only. This press release does not constitute an offer to sell, or
the solicitation of an offer to buy or subscribe for securities. A public
offer in the Federal Republic of Germany and in the Republic of Austria was
made exclusively by means of and on the basis of an English-language
prospectus together with a German-language translation of the summary. The
prospectus was published on the website of the Company and is also
available in printed form free of charge from the Company (Fax
+49-6251-9331-11) and from ODDO SEYDLER BANK AG (Fax +49-69-920-54902).

This press release does not constitute an offer to sell, or the
solicitation of an offer to buy or subscribe for securities in or into the
United States of America, Australia, Canada or Japan or to other
jurisdictions in which publication, release or distribution would be
unlawful. Any securities referred to herein have not been, and will not be,
registered under the U.S. Securities Act of 1933, as amended ("U.S.
Securities Act"). Such securities may not be offered, sold or delivered
within the United States absent from registration under or an applicable
exemption from the registration requirements of the U.S. Securities Act.
Neither BRAIN AG nor any of its shareholders intends to register the
securities referred to in this press release in the United States. The
securities referred to in this press release have not been, and will not
be, registered under the applicable securities laws of Australia, Canada or
Japan. Subject to certain exceptions, the securities may not be offered or
sold in Australia, Canada or Japan or to, or for the account or benefit of,
any national, resident or citizen of Australia, Canada or Japan. There will
be no public offering of securities in the United States or anywhere
outside of the Federal Republic of Germany and the Republic of Austria.

This press release does not constitute an offer document or an offer of
transferable securities to the public in the United Kingdom to which
Section 85 of the U.K. Financial Services and Markets Act 2000 applies and
should not be considered as a recommendation that any person should
subscribe for or purchase any securities as part of the transaction. This
press release is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) to investment
professionals falling within Section 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order")
or (iii) high net worth entities, unincorporated associations and other
persons or entities falling within Section 49 (2), (a) to (d) of the Order
(all such persons together being referred to as "relevant persons"). This
press release or its contents must not be acted or relied on by persons who
are not relevant persons. Any investment or investment activity to which
this press release relates is available only to relevant persons and will
be engaged in only with relevant persons. This release (or parts thereof)
may not be published, reproduced, distributed or made available to third
parties in any other way without the prior consent of BRAIN AG.

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any
forward-looking statements.


---------------------------------------------------------------------------

2016-02-09 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


   Language:    English                                                    
   Company:     B.R.A.I.N. Biotechnology Research And Information Network  
                AG                                                         
                Darmstädter Straße 34-36                                   
                64673 Zwingenberg                                          
                Germany                                                    
   Phone:       +49 (0) 62 51 / 9331-0                                     
   Fax:         +49 (0) 62 51 / 9331-11                                    
   E-mail:      ir@brain-biotech.de                                        
   Internet:    www.brain-biotech.de                                       
   ISIN:        DE0005203947                                               
   WKN:         520394                                                     
   Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated  
                Unofficial Market in Berlin, Dusseldorf, Munich,           
                Stuttgart, Tradegate Exchange                              
 
   
     End of News    DGAP News Service